N7: A novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age Journal Article
| Authors: | Cheung, N. K. V.; Kushner, B. H.; Laquaglia, M.; Kramer, K.; Gollamudi, S.; Heller, G.; Gerald, W.; Yeh, S.; Finn, R.; Larson, S. M.; Wuest, D.; Byrnes, M.; Dantis, E.; Mora, J.; Cheung, I. Y.; Rosenfield, N.; Abramson, S.; O'Reilly, R. J. |
| Article Title: | N7: A novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age |
| Abstract: | Background. The N7 protocol for poor-risk neuroblastoma uses dose-intensive chemotherapy (as in N6 protocol [Kushner et al.:] Clin Oncol 12:2607-2613, 1994] but with lower dosing of vincristine) for induction, surgical resection and 2100 cGy hyperfractionated radiotherapy for local control, and for consolidation, targeted radioimmunotherapy with 131I-labeled anti-GD2 3F8 monoclonal antibody and immunotherapy with unlabeled/unmodified 3F8 (400 mg/m2). Procedure. The chemotherapy consists of: cyclophosphamide 70 mg/kg/d × 2 and a 72-hr infusion of doxorubicin 75 mg/m2 plus vincristine 2 mg/m2, for courses 1, 2, 4, and 6; and cisplatin 50 mg/m2/d × 4 and etoposide 200 mg/m2/d × 3, for courses 3, 5, and 7. 131I-3F8 is dosed at 20 mCi/kg, which is myeloablative and therefore necessitates stem-cell support. Results. Of the first 24 consecutive previously untreated patients more than 1 year old at diagnosis, 22 were stage 4 and two were unresectable stage 3 with MYCN amplification. Chemotherapy achieved CR/VGPR in 21 of 24 patients. Twenty patients to date have completed treatment with 131I-3F8, and 15 patients have completed all treatment. With a median follow-up of 19 months, 18 of 24 patients remain progression-free. Conclusions. Major toxicities were grade 4 myelosuppression and mucositis during chemotherapy, and self-limited pain and urticaria during antibody treatment. Late effects include hearing deficits and hypothyroidism. © 2001 Wiley-Liss, Inc. |
| Keywords: | child; clinical article; treatment outcome; child, preschool; disease-free survival; survival analysis; cisplatin; doxorubicin; cancer combination chemotherapy; dose response; multimodality cancer therapy; conference paper; cancer radiotherapy; chemotherapy, adjuvant; combined modality therapy; radiotherapy, adjuvant; neoplasm staging; gene amplification; etoposide; antineoplastic combined chemotherapy protocols; neoplasm proteins; tumor markers, biological; risk factors; cyclophosphamide; vincristine; monoclonal antibody; antibodies, monoclonal; immunoglobulin g; iodine radioisotopes; neuroblastoma; radiation dose fractionation; genes, myc; remission induction; high risk population; chromosome aberrations; hypothyroidism; dose fractionation; radioimmunotherapy; hyperfractionated radiotherapy; antibody dependent cellular cytotoxicity; complement dependent cytotoxicity; 3f8; immunoconjugates; myeloablative agent; immunization, passive; bone marrow diseases; dose intensity; gross total resection; humans; human; male; female; priority journal; anti-gd2 |
| Journal Title: | Medical and Pediatric Oncology |
| Volume: | 36 |
| Issue: | 1 |
| ISSN: | 0098-1532 |
| Publisher: | Wiley Liss |
| Date Published: | 2001-01-01 |
| Start Page: | 227 |
| End Page: | 230 |
| Language: | English |
| DOI: | 10.1002/1096-911x(20010101)36:1<227::aid-mpo1055>3.0.co;2-u |
| PUBMED: | 11464891 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Presented at the Advances in Neuroblastoma Research Meeting; 1998 Jun 15-17; Bath, England -- Export Date: 22 February 2016 -- Source: Scopus |
Altmetric
Citation Impact
MSK Authors
Related MSK Work